Does a higher Wegovy dose produce more weight loss?

The myth worth correcting first: higher dose doesn't automatically mean faster results for everyone

The assumption many people arrive with is that pushing to the highest dose as quickly as possible is the smartest strategy. It feels logical. If 1.0 mg works, surely 2.4 mg works harder, sooner? In practice, the evidence is more complicated, and reassuring once you understand it.

The STEP 1 trial, published in the New England Journal of Medicine, showed that participants on semaglutide 2.4 mg lost around 15% of body weight on average over 68 weeks. That 15% figure is a trial average across a large population reaching the 2.4 mg maintenance dose; some participants lost considerably more, others less. What the trial couldn't tell us directly is whether rushing the titration improves those outcomes, and clinically, the evidence suggests it doesn't. The step-up schedule is designed so that each dose has time to establish a new equilibrium in appetite regulation before the next increase, which also gives your digestive system a chance to adapt. People who force the pace tend to experience more nausea, vomiting and early discontinuation, which produces far worse results than a methodical climb.

There's also a real phenomenon called a plateau. After significant early weight loss, some people find progress slows at their current dose. That's often when the question of increasing the dose comes up, and it's a legitimate clinical conversation, not one to have alone. If you're wondering whether your Wegovy dose is set to increase and how that process is structured, the guidance on increasing your Wegovy dose explains the process in detail.

What dose-response data does show: higher doses, measurably better average outcomes

Acknowledging the nuance above doesn't mean dose doesn't matter. It does. The dose-response relationship in semaglutide is real and well-documented. Participants maintained on 2.4 mg lose more weight on average than those maintained on 1.7 mg, who in turn tend to do better than those on 1.0 mg. The NHS medicines information for semaglutide notes that the titration schedule builds up to the maintenance dose that produces the medicine's full licensed effect.

The introduction of the 7.2 mg dose (approved by the MHRA in January 2026, with a dedicated single-dose pen approved in April 2026) extended that dose-response curve further. Early data reported around 20.7% average weight loss over 72 weeks at 7.2 mg, narrowing the gap with tirzepatide's results. That's a meaningful difference from the 2.4 mg data, and it matters for patients who plateaued at the original maintenance dose. Worth noting: the 7.2 mg licence applies to adults with a BMI of 30 or above specifically, so it isn't universally available to everyone on Wegovy. Your prescriber confirms eligibility.

The broader picture from the clinical programme is that maximising dose (within what you can tolerate and what is clinically appropriate for you) is associated with better outcomes. The word "tolerate" carries real weight here. If you're curious how your current dose compares across the schedule, the overview of Wegovy dose options lays it out clearly.

Tolerability: the factor that determines whether a dose increase actually helps you

Here's where this question gets personal. If you can't stay on a higher dose because the side effects are unmanageable, that dose isn't producing more weight loss for you, it's producing treatment interruption, which does the opposite. Nausea, vomiting, diarrhoea and constipation are the most common effects and they typically peak in the first one to two weeks after a dose change before settling. But for some people, a particular dose consistently causes problems that don't resolve.

In those cases, prescribers sometimes recommend staying at a lower dose for longer, or moving more slowly through the titration than the standard four-week steps. That's not failure. It's clinical pragmatism, and it often produces better long-term results than forcing a dose that causes someone to stop treatment altogether. If you're finding a step up difficult, that conversation belongs with your prescriber, not a forum. Knowing what to expect can make the difference between pushing through a transient rough patch and stopping prematurely, the page on maximising weight loss on Wegovy covers practical strategies alongside dose management.

We hear regularly from people who feel frustrated that their results have slowed, convinced a higher dose is the missing piece. Sometimes it is. Sometimes other factors (diet quality, sleep, activity, underlying metabolic conditions) matter as much. A prescriber can look at the full picture. For context on the cost implications of moving through doses, the Wegovy pricing page gives an honest overview of what different stages of treatment typically involve.

How prescribers at nume approach dose increase decisions

Every repeat order at nume goes through a clinical review before dispensing, there are no automatic refills. When a dose increase is on the table, a GPhC-registered prescriber looks at your current response, any side effects you've reported, your weight trajectory and your clinical history. That review is done by a real clinician, not automated software. The outcome might be an increase, or it might be a recommendation to stay at your current dose for another cycle while other factors are addressed.

This isn't about slowing you down. It's the same clinical process a GP or specialist would follow, conducted the same day you submit your review. If you want to discuss whether your current dose is still the right one, or whether moving up is appropriate for your situation, speaking to our prescribers is the straightforward next step. You can explore what that looks like on the Wegovy treatment page, or find out more about the clinical team behind these decisions on the clinical team profile.